Genomewide scan for familial combined hyperlipidemia genes in finnish families, suggesting multiple susceptibility loci influencing triglyceride, cholesterol, and apolipoprotein B levels.

Familial combined hyperlipidemia (FCHL) is a common dyslipidemia predisposing to premature coronary heart disease (CHD). The disease is characterized by increased levels of serum total cholesterol (TC), triglycerides (TGs), or both. We recently localized the first locus for FCHL, on chromosome 1q21-q23. In the present study, a genomewide screen for additional FCHL loci was performed. In stage 1, we genotyped 368 polymorphic markers in 35 carefully characterized Finnish FCHL families. We identified six chromosomal regions with markers showing LOD score (Z) values >1.0, by using a dominant mode of inheritance for the FCHL trait. In addition, two more regions emerged showing Z>2.0 with a TG trait. In stage 2, we genotyped 26 more markers and seven additional FCHL families for these interesting regions. Two chromosomal regions revealed Z>2.0 in the linkage analysis: 10p11.2, Z=3.20 (theta=.00), with the TG trait; and 21q21, Z=2.24 (theta=.10), with the apoB trait. Furthermore, two more chromosomal regions produced Z>2.0 in the affected-sib-pair analysis: 10q11.2-10qter produced Z=2.59 with the TC trait and Z=2.29 with FCHL, and 2q31 produced Z=2.25 with the TG trait. Our results suggest additional putative loci influencing FCHL in Finnish families, some potentially affecting TG levels and some potentially affecting TC or apoB levels.

[1]  P. Lipsky,et al.  Detection of familial hypercholesterolemia by assaying functional low-density-lipoprotein receptors on lymphocytes. , 1986, The New England journal of medicine.

[2]  R. S. Spielman,et al.  A genome–wide search for human non–insulin–dependent (type 2) diabetes genes reveals a major susceptibility locus on chromosome 2 , 1996, Nature Genetics.

[3]  M. Eriksson,et al.  Impaired activation of adipocyte lipolysis in familial combined hyperlipidemia. , 1995, The Journal of clinical investigation.

[4]  E. Ruoslahti,et al.  Amino acid sequence of the human fibronectin receptor , 1987, The Journal of cell biology.

[5]  T. Lehtimäki,et al.  Phenotype expression in familial combined hyperlipidemia. , 1997, Atherosclerosis.

[6]  K H Buetow,et al.  A collection of tri- and tetranucleotide repeat markers used to generate high quality, high resolution human genome-wide linkage maps. , 1995, Human molecular genetics.

[7]  A. Chapelle,et al.  Disease gene mapping in isolated human populations: the example of Finland. , 1993, Journal of medical genetics.

[8]  M. Hayden,et al.  Analysis of DNA changes in the LPL gene in patients with familial combined hyperlipidemia. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[9]  Cécile Fizames,et al.  A comprehensive genetic map of the human genome based on 5,264 microsatellites , 1996, Nature.

[10]  J. Browne,et al.  Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. , 1997, Human molecular genetics.

[11]  J. Viikari,et al.  Age and gender specific serum lipid and apolipoprotein fractiles of Finnish children and young adults. The Cardiovascular Risk in Young Finns Study , 1994, Acta paediatrica.

[12]  J. Rotter,et al.  Complex genetic contribution of the Apo AI-CIII-AIV gene cluster to familial combined hyperlipidemia. Identification of different susceptibility haplotypes. , 1997, The Journal of clinical investigation.

[13]  Viikari,et al.  Glucose intolerance in familial combined hyperlipidaemia , 1998 .

[14]  Leena Peltonen,et al.  A putative vulnerability locus to multiple sclerosis maps to 5p14–p12 in a region syntenic to the murine locus Eae2 , 1996, Nature Genetics.

[15]  G. Heiss,et al.  Comparison of nutrient intakes of selected populations in the United States and Israel: the Lipid Research Clinics prevalence study. , 1986, The American journal of clinical nutrition.

[16]  P. Goodfellow,et al.  A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22 , 1996, Nature Genetics.

[17]  A A Schäffer,et al.  Avoiding recomputation in linkage analysis. , 1994, Human heredity.

[18]  J. Ott,et al.  Strategies for multilocus linkage analysis in humans. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[19]  M. King,et al.  Linkage of early-onset familial breast cancer to chromosome 17q21. , 1990, Science.

[20]  T. Aitman,et al.  Defects of insulin action on fatty acid and carbohydrate metabolism in familial combined hyperlipidemia. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[21]  J. Ott.  Analysis of Human Genetic Linkage , 1985 .

[22]  D. Pollen,et al.  The genetic defect causing familial Alzheimer's disease maps on chromosome 21. , 1987, Science.

[23]  S. Baekkeskov,et al.  Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase , 1990, Nature.

[24]  J. Graaf,et al.  Defects of lipoprotein metabolism in familial combined hyperlipidaemia. , 1998, Current opinion in lipidology.

[25]  M. Farrall,et al.  Complex segregation analysis provides evidence for a major gene acting on serum triglyceride levels in 55 British families with familial combined hyperlipidemia. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[26]  A A Schäffer,et al.  Faster sequential genetic linkage computations. , 1993, American journal of human genetics.

[27]  S. Grundy,et al.  Familial combined hyperlipidemia workshop , 1989 .

[28]  Eric Lander,et al.  Linkage disequilibrium mapping in isolated founder populations: diastrophic dysplasia in Finland , 1992, Nature Genetics.

[29]  M. Pericak-Vance,et al.  Linkage studies in familial Alzheimer disease: evidence for chromosome 19 linkage. , 1991, American journal of human genetics.

[30]  E. Wijsman,et al.  Evidence against linkage of familial combined hyperlipidemia to the apolipoprotein AI-CIII-AIV gene complex. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[31]  A. Aro,et al.  Family study of serum lipids and lipoproteins in coronary heart-disease. , 1973, Lancet.

[32]  J. Weissenbach,et al.  A genome-wide search for chromosomal loci linked to bipolar affective disorder in the Old Order Amish , 1996, Nature Genetics.

[33]  J D Terwilliger,et al.  A novel polylocus method for linkage analysis using the lod‐score or affected sib‐pair method , 1993, Genetic epidemiology.

[34]  G. Reaven.  Role of Insulin Resistance in Human Disease , 1988, Diabetes.

[35]  H. Blackburn,et al.  Cardiovascular survey methods. , 1969, Monograph series. World Health Organization.

[36]  M. McCarthy,et al.  Mapping of a gene for type 2 diabetes associated with an insulin secretion defect by a genome scan in Finnish families , 1996, Nature Genetics.

[37]  L. Kiemeney,et al.  A common genetic mechanism determines plasma apolipoprotein B levels and dense LDL subfraction distribution in familial combined hyperlipidemia. , 1998, American journal of human genetics.

[38]  Richard H. Myers,et al.  Familial Lipoprotein Disorders in Patients With Premature Coronary Artery Disease , 1992, Circulation.

[39]  N Risch,et al.  Model misspecification and multipoint linkage analysis. , 1992, Human heredity.

[40]  D. Kromhout,et al.  A frequently occurring mutation in the lipoprotein lipase gene (Asn291Ser) contributes to the expression of familial combined hyperlipidemia. , 1995, Human molecular genetics.

[41]  M. Hayden,et al.  Lack of association of the apolipoprotein A-I-C-III-A-IV gene XmnI and SstI polymorphisms and of the lipoprotein lipase gene mutations in familial combined hyperlipoproteinemia in French Canadian subjects. , 1996, Journal of lipid research.

[42]  R. Deitch.  Commentary from Westminster , 1981, The Lancet.

[43]  T. Lehtimäki,et al.  Linkage of familial combined hyperlipidaemia to chromosome 1q21–q23 , 1998, Nature Genetics.

[44]  E. Wijsman,et al.  Genetic predictors of FCHL in four large pedigrees. Influence of ApoB level major locus predicted genotype and LDL subclass phenotype. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[45]  S. Deeb,et al.  A mutation in the promoter of the lipoprotein lipase (LPL) gene in a patient with familial combined hyperlipidemia and low LPL activity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[46]  P. Arner.  Is familial combined hyperlipidaemia a genetic disorder of adipose tissue? , 1997, Current opinion in lipidology.

[47]  E. Vartiainen,et al.  Twenty-year trends in coronary risk factors in north Karelia and in other areas of Finland. , 1994, International journal of epidemiology.

[48]  L. Peltonen,et al.  Messages from an isolate: lessons from the Finnish gene pool. , 1995, Biological chemistry Hoppe-Seyler.

[49]  M. Farrall,et al.  Familial combined hyperlipidaemia linked to the apolipoprotein AI–CIII–AIV gene cluster on chromosome 11q23q–q24 , 1991, Nature.

[50]  A. Motulsky,et al.  Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. , 1973, The Journal of clinical investigation.

[51]  W. Sluiter,et al.  Patients with combined hypercholesterolemia-hypertriglyceridemia show an increased monocyte-endothelial cell adhesion in vitro: triglyceride level as a major determinant. , 1991, Metabolism: clinical and experimental.

[52]  C. Shoulders,et al.  Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. , 1993, The Journal of clinical investigation.

[53]  S. Baekkeskov,et al.  Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase , 1990, Nature.